Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.

NCT01690260 is registered in ClinicalTrials.gov with Northern Orthopaedic Division, Denmark as lead sponsor.

NCT NCT01690260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01690260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.
Lead sponsor
Northern Orthopaedic Division, Denmark
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2004
Completion date
October 2, 2017
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone degenerative changes, degenerative disorder of bone, osteoarthritis